Digest Network Come funziona
Network
/
Società
Sa
Non verificato

Savara Inc.

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaMedicina - VarieSalute

90 comunicati stampa

Guarda tutti i comunicati
21/10/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Industria
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
12/10/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Fiere
Industria
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
24/08/2026
Fiere
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
20/08/2026
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Savara Announces New Employment Inducement Grant
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
11/08/2026
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Sanità
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
30/07/2026
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
12/06/2026
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Savara Announces New Employment Inducement Grant
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
08/06/2026
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Savara Announces Chief Financial and Administrative Officer Transition
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Web e Social Network
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
20/05/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Industria
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0